Brief: Transgene, Bioinvent Get ANSM Approval For Phase I/IIa Trial

Transgene SA

19/01/2021 06:39

Jan 19 (Reuters) - BioInvent International AB  BINV.ST :
    * TRANSGENE AND BIOINVENT RECEIVE APPROVAL FROM ANSM TO
PROCEED
WITH PHASE I/IIA TRIAL OF ANTI-CTLA4-ARMED ONCOLYTIC VIRUS
BT-001 IN SOLID TUMORS
    * FIRST PATIENT IS EXPECTED TO BE ENROLLED IN THIS TRIAL IN
UPCOMING WEEKS

Source text for Eikon:  ID:nBwbFCNXra 
Further company coverage:  BINV.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))